Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment.
Drug Res (Stuttg)
; 71(3): 138-148, 2021 Mar.
Article
in English
| MEDLINE | ID: covidwho-894442
ABSTRACT
Remdesivir is presently been considered as 'molecule of hope' to curb the menace of COVID19. Non-availability of any USFDA approved drug has led to several attempt of drug-repurposing and development of new therapeutic molecules. However, Remdesivir has been found to be effective against a broad range of virus including SARS, MERS and COVID 19 through in-vitro studies. Several clinical research attempt are presently being conducted showing promising result yet not conclusive. This review summarized all such clinical trials to critically appraise the usage of Remdesivir against COVID 19 along with the publications related to the results of the clinical studies. The present regulatory aspect i. e. Emergency Use Authorization (EYA) and information of molecule and plausible mechanism is also dealt.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Adenosine Monophosphate
/
Alanine
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
Drug Res (Stuttg)
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS